Literature DB >> 15481612

Myelodysplastic syndrome with erythroid aplasia following pure red cell aplasia.

Hyoung Doo Kim1, Kee Won Kim, Suk Young Park, Hyeok Jae Ko, Young Yong An, So Young Shin, Ji Young Jang.   

Abstract

Myelodysplastic syndrome (MDS) with erythroid aplasia is a very rare disorder that has not been clearly defined. We experienced a case of pure red cell aplasia (PRCA), which evolved to MDS with erythroid aplasia. A 59-year-old male with transfusion-dependent PRCA was referred to our hospital for an evaluation of newly developed thrombocytopenia. Two years ago, PRCA was diagnosed by the laboratory findings and a bone marrow examination, which showed no evidence of any myelodysplastic features and thymoma. Upon admission, the bone marrow findings showed marked hypercellularity. with numerous dysplastic features in the three lineages including erythroid hypoplasia. These findings were compatible with a diagnosis of MDS with red cell aplasia. It is very interesting that the PRCA evolved to MDS with red cell aplasia, which strongly suggests an autoimmune mechanism for the development of MDS.

Entities:  

Mesh:

Year:  2004        PMID: 15481612      PMCID: PMC4531565          DOI: 10.3904/kjim.2004.19.3.193

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  10 in total

Review 1.  Pure red cell aplasia.

Authors:  P Fisch; R Handgretinger; H E Schaefer
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 2.  A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

Authors:  C Rosenfeld; A List
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

3.  Preleukemic states.

Authors:  R V Pierre
Journal:  Semin Hematol       Date:  1974-01       Impact factor: 3.851

4.  Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia.

Authors:  F R Appelbaum; J Barrall; R Storb; R Ramberg; K Doney; G E Sale; E D Thomas
Journal:  Exp Hematol       Date:  1987-12       Impact factor: 3.084

5.  Studies on pure red cell aplasia. X. Association with acute leukemia and significance of bone marrow karyotype abnormalities.

Authors:  E N Dessypris; A Fogo; M Russell; E Engel; S B Krantz
Journal:  Blood       Date:  1980-09       Impact factor: 22.113

6.  Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients.

Authors:  D A Clark; E N Dessypris; S B Krantz
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

Review 7.  Myelodysplastic syndrome with erythroid hypoplasia/aplasia: a case report and review of the literature.

Authors:  J García-Suárez; T Pascual; M A Muñoz; B Herrero; A Pardo
Journal:  Am J Hematol       Date:  1998-08       Impact factor: 10.047

8.  Red cell aplasia in myelodysplastic syndrome.

Authors:  P J Williamson; D G Oscier; A J Bell; T J Hamblin
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

9.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

Authors:  G Socié; M Henry-Amar; A Bacigalupo; J Hows; A Tichelli; P Ljungman; S R McCann; N Frickhofen; E Van't Veer-Korthof; E Gluckman
Journal:  N Engl J Med       Date:  1993-10-14       Impact factor: 91.245

10.  The pathophysiology of pure red cell aplasia: implications for therapy.

Authors:  R J Charles; K M Sabo; P G Kidd; J L Abkowitz
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

  10 in total
  1 in total

1.  Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.

Authors:  Anh Khoi Vo; Hilde Kollsete Gjelberg; Randi Hovland; Marte Karen Lindstad Brattås; Øystein Bruserud; Håkon Reikvam
Journal:  Case Rep Hematol       Date:  2020-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.